Michelle Laspaluto Sells 2,260 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) CFO Michelle Laspaluto sold 2,260 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.51, for a total value of $10,192.60. Following the completion of the transaction, the chief financial officer now directly owns 172,977 shares of the company's stock, valued at approximately $780,126.27. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michelle Laspaluto also recently made the following trade(s):

• On Thursday, January 30th, Michelle Laspaluto sold 1,015 shares of Chimerix stock. The stock was sold at an average price of $4.11, for a total value of $4,171.65.

Chimerix Stock Performance

Chimerix stock traded up $0.65 during trading on Tuesday, hitting $5.03. The company's stock had a trading volume of 3,540,371 shares, compared to its average volume of 1,520,251. The stock has a market capitalization of $452.49 million, a price-to-earnings ratio of -5.37 and a beta of 0.35. The stock's fifty day moving average is $3.60 and its 200 day moving average is $1.85. Chimerix, Inc. has a 1-year low of $0.75 and a 1-year high of $5.15.

Institutional Investors Weigh In On Chimerix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stoneridge Investment Partners LLC increased its stake in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock worth $154,000 after acquiring an additional 8,134 shares during the last quarter. Bender Robert & Associates acquired a new stake in Chimerix during the fourth quarter worth about $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Chimerix during the fourth quarter worth about $59,000. Jane Street Group LLC acquired a new stake in Chimerix during the fourth quarter worth about $62,000. Finally, Diadema Partners LP acquired a new stake in Chimerix during the fourth quarter worth about $101,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CMRX has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Chimerix in a research note on Monday, December 30th. Wedbush reiterated an "outperform" rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.